Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: The role of the CNR1, CNR2 and FAAH genes

Journal of Psychopharmacology

Volumn 26, Issue 10, 2012, Pages 1391-1398

  Mitjans, Marina ^a   Gastó, Cristóbal ^b,c   Catalán, Rosa ^b,c   Fañanás, Lourdes ^a,c   Arias, Bárbara ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

endocannabinoid system; Major depression; molecular variation; pharmacogenetics; SSRI

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CITALOPRAM; ENDOCANNABINOID; FATTY ACID AMIDASE;

ADULT; ALLELE; ARTICLE; CANNABINOID 1 RECEPTOR GENE; CANNABINOID 2 RECEPTOR GENE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG RESPONSE; FATTY ACID AMIDE HYDROLASE GENE; FEMALE; FOLLOW UP; GENE; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PHARMACOGENETICS; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION;

ADULT; AMIDOHYDROLASES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HETEROZYGOTE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SPAIN;

EID: 84866256149     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112454229     Document Type: Article

References (67)

1. Adamczyk P, Golda A, McCreary AC, et al. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol. 2008 ; 59: 217-228
2. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association ; 1994
3. Arias B, Serretti A, Lorenzi C, et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of european origin. J Affect Disord. 2006 ; 90: 251-256
4. Arias B, Serretti A, Mandelli L, et al. Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenet Genomics. 2009 ; 19: 121-128
5. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use?. Schizophr Bull. 2008 ; 34: 1130-1144
6. Balazsa T, Biro J, Gullai N, et al. CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus. Neurochem Int. 2008 ; 52: 95-102
7. Bambico FR, Katz N, Debonnel G, et al. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci. 2007 ; 27: 11700-11711
8. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996 ; 16: 307-314
9. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995 ; 57: 289-300
10. Biver F, Lotstra F, Monclus M, et al. Sex difference in 5HT2 receptor in the living human brain. Neurosci Lett. 1996 ; 204: 25-28
11. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet. 2001 ; 2: 91-99
12. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003 ; 301: 386-389
13. Chiang KP, Gerber AL, Sipe JC, et al. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet. 2004 ; 13: 2113-2119
14. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007 ; 370: 1706-1713
15. Claassen CA, Trivedi MH, Rush AJ, et al. Clinical differences among depressed patients with and without a history of suicide attempts: findings from the Star*D Trial. J Affect Disord. 2007 ; 97: 77-84
16. Cohen J Statistical Power Analysis for the Behavioral Sciences. New Jersey: Hillsdale ; 1988: 8-14.
17. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996 ; 384: 83-87
18. Dean AG, Dean JA, Burton AH, et al. Epi Info: a general-purpose microcomputer program for public health information systems. Am J Prev Med. 1991 ; 7: 178-182
19. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002 ; 99: 10819-10824
20. Domschke K, Danniowski U, Ohrmann P, et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. European Neuropsychopharmacology. 2008 ; 18: 751-759
21. Drago A, Crisafulli C, Sidoti A, et al. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol. 2011 ; 94: 418-460
22. Forman EM, Berk MS, Henriques GR, et al. History of multiple suicide attempts as a behavioral marker of severe psychopathology. Am J Psychiatry. 2004 ; 161: 437-443
23. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991 ; 48: 851-855
24. Freedman ML, Reich D, Penney KL, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet. 2004 ; 36: 388-393
25. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 ; 232: 54-61
26. Gilmer WS, Gollan JK, Wisniewski SR, et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? A Star*D Report. J Clin Psychiatry. 2008 ; 69: 1246-1256
27. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A. 2005 ; 102: 18,620-18,625
28. Hansen PE, Wang AG, Stage KB, et al. Comorbid personality disorder predicts suicide after major depression: a 10-year follow-up. Acta Psychiatr Scand. 2003 ; 107: 436-440
29. Herkenham M. Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res Monogr. 1991 ; 112: 129-145
30. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav Pharmacol. 2005a ; 16: 333-352
31. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the Rat Forced Swim Test. Eur Neuropsychopharmacol. 2005b ; 15: 593-599
32. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the Rat Forced Swim Test. Eur Neuropsychopharmacol. 2005c ; 15: 593-599
33. Hill MN, Ho WS, Sinopoli KJ, et al. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology. 2006 ; 31: 2591-2599
34. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009 ; 124: 57-73
35. Juhasz G, Chase D, Pegg E, et al. CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology. 2009 ; 34: 2019-2027
36. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010 ; 15: 473-500
37. Kendler KS, Gardner CO, Neale MC, et al. Genetic risk factors for major depression in men and women: similar or different heritabilities and same or partly distinct genes?. Psychol Med. 2001 ; 31: 605-616
38. Klengel T, Binder EB. Using gene-environment interactions to target personalized treatment in mood disorder. Per Med. 2011 ; 8: 23-34
39. Koethe D, Llenos IC, Dulay JR, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm. 2007 ; 114: 1055-1063
40. Komar AA. Genetics. SNPs, silent but not invisible. Science. 2007 ; 315: 466-467
41. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001 ; 56: 1059-1068
42. Lazary J, Juhasz G, Hunyady L, et al. Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci. 2011 ; 32: 270-280
43. Lazary J, Lazary A, Gonda X, et al Am J Med Genet B Neuropsychiatr Genet. 150B: ; 2009: 1118-1127.
44. Legato MJ. The skewed sex distribution in affective disorders-a diagnostic, social, or biological problem?. Prog Brain Res. 2010 ; 186: 159-166
45. Martin M, Ledent C, Parmentier M, et al. Involvement of CB1 Cannabinoid Receptors in Emotional Behaviour. Psychopharmacology. 2002 ; 159: 379-387
46. Martin RM, Hilton SR, Kerry SM, et al. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. BMJ. 1997 ; 314: 646-651
47. Monteleone P, Bifulco M, Maina G, et al. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res. 2010 ; 61: 400-404
48. Nierenberg A. Predictors of response to antidepressants general principals and clinical implications. Psychiatr Clin North Am. 2003 ; 26: 345-352
49. Nishizawa S, Benkelfat C, Young SN, et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A. 1997 ; 94: 5308-5313
50. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method for the determination of citalopram and desmethylcitalopram in serum without interference from commonly used psychotropic drugs and their metabolites. J Chromatogr B Biomed Appl. 1996 ; 675: 83-88
51. Onaivi ES. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology. 2006 ; 54: 231-246
52. Onaivi ES, Ishiguro H, Gong J-P, et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One. 2008 ; 3 ( 2 ):
53. Ortega-Alvaro A, Aracil-Fernandez A, Ternianov A, et al. Deletion of cannabinoid receptor 2 increased ethanol abuse vulnerability associated to alterations in mu-opioid receptor gene expression in mice. Eur Neuropsychopharmacol. 2011 ; 21: S572 - S572
54. Porcelli S, Drago A, Fabbri C, et al. Mechanisms of antidepressant action: an integrated dopaminergic perspective. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 1532-1543
55. Racz I, Nadal X, Alferink J, et al. Interferon-gamma is a critical modulator of CB2 cannabinoid receptor signaling during neuropathic pain. J Neurosci. 2008a ; 28: 12,136-12,145
56. Racz I, Nadal X, Alferink J, et al. Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci. 2008b ; 28: 12,125-12,135
57. Rodriguez de Fonseca F, del Arco I, Bermudez-Silva FJ, et al. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005 ; 40: 2-14
58. Roy A. Features associated with suicide attempts in depression: a partial replication. J Affect Disord. 1993 ; 27: 35-38
59. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, et al. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007 ; 67: 9609-9612
60. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 2008 ; 8: 90-100
61. Spitzer RL, Williams JB, Gibbon M, First MEB Structured Clinical Interview for DSM-III-R. Washington DC: American Psychiatric Press ; 1990
62. Suarez J, Bermudez-Silva FJ, Mackie K, et al. Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol. 2008 ; 509: 400-421
63. Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry. 2011 ; 19: 109-124
64. Vermeiden M, Van den Broek WW, Mulder PGH, et al. Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. J Psychopharmacol. 2010 ; 24: 497-502
65. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996 ; 276: 293-299
66. Witkin JM, Tzavara ET, Davis RJ, et al. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci. 2005 ; 26: 609-617
67. Zisook S, Lesser I, Stewart JW, et al. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry. 2007 ; 164: 1539-1546